Mystic Asset Management Inc. Acquires New Holdings in Zoetis Inc. (NYSE:ZTS)

Mystic Asset Management Inc. bought a new position in Zoetis Inc. (NYSE:ZTS) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 5,701 shares of the company’s stock, valued at approximately $929,000.

A number of other hedge funds have also added to or reduced their stakes in ZTS. Leelyn Smith LLC boosted its stake in shares of Zoetis by 3.4% in the 4th quarter. Leelyn Smith LLC now owns 22,433 shares of the company’s stock worth $3,655,000 after buying an additional 744 shares during the last quarter. Cibc World Markets Corp boosted its position in Zoetis by 15.5% in the fourth quarter. Cibc World Markets Corp now owns 71,255 shares of the company’s stock worth $11,610,000 after purchasing an additional 9,574 shares during the last quarter. Polen Capital Management LLC grew its stake in shares of Zoetis by 17.5% during the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock valued at $1,219,237,000 after purchasing an additional 1,116,541 shares during the period. Arbor Capital Management Inc. ADV grew its stake in shares of Zoetis by 7.3% during the 4th quarter. Arbor Capital Management Inc. ADV now owns 5,806 shares of the company’s stock valued at $986,000 after purchasing an additional 395 shares during the period. Finally, Signature Wealth Management Group increased its position in shares of Zoetis by 9.0% during the 4th quarter. Signature Wealth Management Group now owns 9,519 shares of the company’s stock valued at $1,551,000 after purchasing an additional 784 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,862 shares of company stock worth $312,254. Insiders own 0.16% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $165.39 on Tuesday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The business has a 50-day moving average price of $166.82 and a 200-day moving average price of $175.97. The firm has a market cap of $74.06 billion, a price-to-earnings ratio of 30.24, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.21%. Zoetis’s payout ratio is 36.56%.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of research reports. Morgan Stanley dropped their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Barclays boosted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.